129 related articles for article (PubMed ID: 38494236)
1. Application of sodium sulfobutylether-β-cyclodextrin based on encapsulation.
Huang J; Wang X; Huang T; Yang Y; Tu J; Zou J; Yang H; Yang R
Carbohydr Polym; 2024 Jun; 333():121985. PubMed ID: 38494236
[TBL] [Abstract][Full Text] [Related]
2. Cyclodextrins: Efficient biocompatible solubilizing excipients for bromhexine liquid and semi-solid drug delivery systems.
Stojanov M; Nielsen HM; Larsen KL
Int J Pharm; 2012 Jan; 422(1-2):349-55. PubMed ID: 22027391
[TBL] [Abstract][Full Text] [Related]
3. Sulfobutylether-β-cyclodextrin: A functional biopolymer for drug delivery applications.
Pardeshi CV; Kothawade RV; Markad AR; Pardeshi SR; Kulkarni AD; Chaudhari PJ; Longhi MR; Dhas N; Naik JB; Surana SJ; García MC
Carbohydr Polym; 2023 Feb; 301(Pt B):120347. PubMed ID: 36446486
[TBL] [Abstract][Full Text] [Related]
4. Comparison of sulfobutylether- and sulfated-beta-cyclodextrins as additives for the chiral separation of basic spirobenzopyrans by capillary electrophoresis.
Morin P; Dreux M; Usse S; Viaud MC; Guillaumet G
Electrophoresis; 1999 Sep; 20(13):2630-7. PubMed ID: 10532328
[TBL] [Abstract][Full Text] [Related]
5. Characterization of Thymoquinone-Sulfobutylether-β-Cyclodextrin Inclusion Complex for Anticancer Applications.
Eid EEM; Almaiman AA; Alshehade SA; Alsalemi W; Kamran S; Suliman FO; Alshawsh MA
Molecules; 2023 May; 28(10):. PubMed ID: 37241838
[TBL] [Abstract][Full Text] [Related]
6. Inclusion complexation of lorazepam with different cyclodextrins suitable for parenteral use.
Holvoet C; Vander Heyden Y; Plaizier-Vercammen J
Drug Dev Ind Pharm; 2005 Jul; 31(6):567-75. PubMed ID: 16109630
[TBL] [Abstract][Full Text] [Related]
7. Application of sulfobutylether-beta-cyclodextrin with specific degrees of substitution for the enantioseparation of pharmaceutical mixtures by capillary electrophoresis.
Skanchy DJ; Xie GH; Tait RJ; Luna E; Demarest C; Stobaugh JF
Electrophoresis; 1999 Sep; 20(13):2638-49. PubMed ID: 10532329
[TBL] [Abstract][Full Text] [Related]
8. Inclusion complexes of trihexyphenidyl with natural and modified cyclodextrins.
Maeda H; Tanaka R; Nakayama H
Springerplus; 2015; 4():218. PubMed ID: 26020020
[TBL] [Abstract][Full Text] [Related]
9. Inclusion complexation of diazepam with different cyclodextrins in formulations for parenteral use.
Holvoet C; Heyden YV; Plaizier-Vercammen J
Pharmazie; 2005 Aug; 60(8):598-603. PubMed ID: 16124403
[TBL] [Abstract][Full Text] [Related]
10. Cyclodextrin-catalyzed deacetylation of spironolactone is pH and cyclodextrin dependent.
Jarho P; Vander Velde D; Stella VJ
J Pharm Sci; 2000 Feb; 89(2):241-9. PubMed ID: 10688753
[TBL] [Abstract][Full Text] [Related]
11. Preparation, optimization of the inclusion complex of glaucocalyxin A with sulfobutylether-β-cyclodextrin and antitumor study.
Ren L; Wang J; Chen G
Drug Deliv; 2019 Dec; 26(1):309-317. PubMed ID: 30896265
[TBL] [Abstract][Full Text] [Related]
12. A comparative study on inclusion complex formation between formononetin and β-cyclodextrin derivatives through multiscale classical and umbrella sampling simulations.
Bhardwaj VK; Purohit R
Carbohydr Polym; 2023 Jun; 310():120729. PubMed ID: 36925262
[TBL] [Abstract][Full Text] [Related]
13. A luminescence study of the interaction of sulfobutylether-β-cyclodextrin with rutin.
Wu M; Song Z; Zhang J
Drug Metab Lett; 2011 Dec; 5(4):259-66. PubMed ID: 22292472
[TBL] [Abstract][Full Text] [Related]
14. Influence of preparation method on itraconazole oral solutions using cyclodextrins as complexing agents.
Holvoet C; Vander Heyden Y; Plaizier-Vercammen J
Pharmazie; 2007 Jul; 62(7):510-4. PubMed ID: 17718191
[TBL] [Abstract][Full Text] [Related]
15. Controlled and complete release of a model poorly water-soluble drug, prednisolone, from hydroxypropyl methylcellulose matrix tablets using (SBE)(7m)-beta-cyclodextrin as a solubilizing agent.
Rao VM; Haslam JL; Stella VJ
J Pharm Sci; 2001 Jul; 90(7):807-16. PubMed ID: 11458330
[TBL] [Abstract][Full Text] [Related]
16. Effect of mechanochemical inclusion of triamterene into sulfobutylether-β-cyclodextrin and its improved dissolution behavior.
Maeda H; Shiobara R; Tanaka M; Kajinami A; Nakayama H
Drug Dev Ind Pharm; 2021 Apr; 47(4):535-541. PubMed ID: 33185132
[TBL] [Abstract][Full Text] [Related]
17. Enhancing the Anti-Leukemic Potential of Thymoquinone/Sulfobutylether-β-cyclodextrin (SBE-β-CD) Inclusion Complexes.
Eid EEM; Alshehade SA; Almaiman AA; Kamran S; Lee VS; Alshawsh MA
Biomedicines; 2023 Jul; 11(7):. PubMed ID: 37509531
[TBL] [Abstract][Full Text] [Related]
18. Fabrication of sulfobutylether-β-cyclodextrin/glabridin inclusion complex for promoting bioactivities.
Wang W; Tang K; Huang C; Liu A
Arch Pharm (Weinheim); 2024 May; ():e2400082. PubMed ID: 38724255
[TBL] [Abstract][Full Text] [Related]
19. Preparation, characteristic and pharmacological study on inclusion complex of sulfobutylether-β-cyclodextrin with glaucocalyxin A.
Ren L; Jing J; Chen G; Miao Y; Wei P
J Pharm Pharmacol; 2014 Jul; 66(7):927-34. PubMed ID: 24697809
[TBL] [Abstract][Full Text] [Related]
20. Controlled porosity-osmotic pump pellets of a poorly water-soluble drug using sulfobutylether-beta-cyclodextrin, (SBE) 7M-beta-CD, as a solubilizing and osmotic agent.
Sotthivirat S; Haslam JL; Stella VJ
J Pharm Sci; 2007 Sep; 96(9):2364-74. PubMed ID: 17497739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
